Blackstone Has Quietly Invested in Life Sciences for Years. Now Its Bet Could Pay Off. | ALNY Message Board Posts

Alnylam Pharmaceuticals

  ALNY website

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34961 of 34968  at  2/21/2021 10:20:28 AM  by

Steve_382


Blackstone Has Quietly Invested in Life Sciences for Years. Now Its Bet Could Pay Off.

 Excerpt from this article in Barron's:
 
 
 

If Blackstone succeeds in life sciences, the company could not only lift its own fortunes but also provide a road map for other big investors in the increasingly prominent field.

There’s no better illustration of the strategy than Blackstone’s nearly $2 billion investment in Alnylam Pharmaceuticals (ALNY) around the time of the Covid outbreak last year. The Cambridge, Mass., company develops RNA-based drugs much like Moderna (MRNA) and Pfizer (PFE) and BioNTech (BNTX) in their innovative Covid-19 vaccines. However, Alnylam uses it to treat other diseases.

Alnylam was already working with Novartis (NVS) to develop cholesterol-fighting drug inclisiran, but it needed more money to develop other RNA treatments, and the stock and bond markets were in a shambles.

In April, Blackstone, already the landlord of Alnylam’s lab, stepped in with $1 billion for half of the inclisiran sales royalties. It bought $100 million of Alnylam shares, invested $150 million in its cardiometabolic-disease therapies, one of which showed positive Phase-3 clinical trial results last month, and made a $750 million loan. In short, Blackstone’s approach is all-encompassing, as landlord, scientific partner, investor, advisor, and lender.

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...